Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Trodelvy(Sacituzumab Govitecan-Hziy)Gilead Sciences, Inc. logoGILD

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Gilead Sciences, Inc.

$6.2M

Medicare cost, 2024

Medicare drug plans spent $6.2 million on Trodelvy (sacituzumab govitecan-hziy) in 2024, for 319 prescriptions and refills filled by 67 patients. Spending rose 36% from 2023 to 2024. At about $19,509 per prescription it is a high-cost drug. New York accounts for the most spending ($1.5 million, 24% of the total).

Medicare cost, 2024

$6.2M

+36.3% from 2023

Prescriptions

319

$19,509.31 per claim

Patients

67

68 prescribers

Total spending, 2024

$6.2M

$92,887.61 per patient

Questions and answers

How much does Medicare spend on Trodelvy?

Medicare prescription drug plans paid $6.2M for Trodelvy in 2024, for 319 prescriptions and refills to 67 patients (up 36.3% from 2023). The average cost per claim was $19,509.31.

Which state spends the most on Trodelvy?

New York had the highest Medicare cost for Trodelvy in 2024: $1.5M for 73 claims, followed by California ($872K).

Who prescribes Trodelvy the most?

Samer S Kasbari, hematology-oncology in Goldsboro, NC, had the highest Medicare cost for Trodelvy in 2024: 12 claims costing $354K.

Who makes Trodelvy?

Trodelvy is made by Gilead Sciences, Inc. (GILD), listed in the Medicare spending data as Gilead Sciences.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Trodelvy was $6.2M in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Trodelvy, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Samer S Kasbari Goldsboro, NCHematology-Oncology12Under 11$354K
Syed S Rafique Greenwood, MSHematology-Oncology15Under 11$329K
1407859259 Hematology-Oncology11Under 11$296K
Rohit Kapoor Live Oak, TXHematology-Oncology14Under 11$274K
Satish A Shah Gettysburg, PAHematology-Oncology18Under 11$218K
Anna A Niewiarowska Bethlehem, PAHematology-Oncology14Under 11$205K

Prescriber data by year

YearPrescribersClaimsPatientsCost
20223515335$3.0M
20235523163$4.6M
20246831967$6.2M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Gilead SciencesGILD logoGILD319$6.2M

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube